


Cerebrio
220 East 42nd Street
5th Floor
New York, NY 10017

SAFELY TREATING OAB IN THE ELDERLY PATIENT:

Thinking Beyond the Bladder



Friday, May 4, 2007

7:00 AM – 7:30 AM **Registration and Breakfast**

7:30 AM – 9:30 AM **Scientific Session**

The Sheraton Seattle Hotel

1400 6th Avenue
Seattle, Washington
Room: Metropolitan A (Level 3)

Program Moderator

Joseph G. Ouslander, MD

Faculty

Jeanette S. Brown, MD

Gary G. Kay, PhD

Peter R. Kowey, MD

Thomas E. Lackner, PharmD, CGP, FASCP

A breakfast symposium to be held during the American Geriatrics Society 2007 Annual Scientific Meeting.

This symposium is supported by an educational grant from Novartis Pharmaceuticals.

PROGRAM OVERVIEW

Overactive bladder (OAB) is a prevalent condition that increases in incidence with age. Compared to their younger counterparts, older patients are more susceptible to drug-induced adverse events, have an increased incidence of conditions likely to be exacerbated by drug therapy, and are more likely to receive polypharmacy.

The most effective treatment for OAB is a combination of behavioral therapy and pharmacologic treatment with anticholinergic agents. Each of the available agents for the treatment of OAB is effective at blocking the cholinergic receptors in the bladder, and thereby alleviating symptoms. The blockade of these receptors in places other than the bladder, however, results in anticholinergic side effects such as dry mouth, headache, constipation, blurred vision, and dry eyes. While many anticholinergic side effects might be considered simply an annoyance, some are potentially serious, such as cognitive and cardiac adverse events.

This symposium will be moderated by a geriatrician and will feature the expert opinions of a multidisciplinary panel, including a urologist, cardiologist, neuropsychologist, and doctor of pharmacy.

LEARNING OBJECTIVES

After completing this program, participants should be better able to:

- Identify the etiologies of OAB in geriatric patients
- List the factors that put older patients at increased risk for pharmacologic side effects
- Describe the potential for cognitive and cardiac side effects of anticholinergic therapy
- Select current drug treatments for OAB considering safety and efficacy in geriatric patients

PROGRAM AGENDA

7:00 AM – 7:30 AM	Registration and Breakfast	
7:30 AM – 7:35 AM	Welcome and Introduction	Joseph G. Ouslander, MD
7:35 AM – 8:00 AM	Practical Diagnosis and Management of OAB in Older Patients	Jeanette S. Brown, MD
8:00 AM – 8:25 AM	Pharmacologic Treatment of the Older OAB Patient	Thomas E. Lackner, PharmD, CGP, FASCP
8:25 AM – 8:50 AM	Cardiovascular Considerations in the Use of Anticholinergic Medications	Peter R. Kowey, MD
8:50 AM – 9:15 AM	Anticholinergic Therapy and the CNS: Cognition Versus Continence?	Gary G. Kay, PhD
9:15 AM – 9:30 AM	Question and Answer Session	Faculty

FACULTY

Program Moderator

Joseph G. Ouslander, MD

Professor of Medicine and Nursing
Director, Division of Geriatric Medicine and Gerontology
Chief Medical Officer
Emory University
Atlanta, Georgia

Faculty

Jeanette S. Brown, MD

Professor, Departments of Obstetrics, Gynecology & Reproductive Sciences; Urology; and Epidemiology & Biostatistics
Director, UCSF Women's Continence Center
University of California, San Francisco
San Francisco, California

Gary G. Kay, PhD

Associate Professor of Neurology
Georgetown University School of Medicine
Medical Staff, Georgetown University Hospital
Washington, District of Columbia

Peter R. Kowey, MD

Professor of Medicine and Clinical Pharmacology
Thomas Jefferson University
Philadelphia, Pennsylvania
Chief, Division of Cardiovascular Diseases
Main Line Health System
Wynnewood, Pennsylvania

Thomas E. Lackner, PharmD, CGP, FASCP

Professor of Pharmacy
Institute for the Study of Geriatric Pharmacotherapy
University of Minnesota College of Pharmacy
Minneapolis, Minnesota

CME Information

Accreditation

The American Geriatrics Society (AGS) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Continuing Education Hours

The AGS designates this continuing medical education activity for a maximum of 2 *AMA PRA Category 1 Credits*[™]. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Target Audience

This continuing medical education offering is intended for physicians who specialize in primary and specialty care of older adults, geriatric nurse practitioners, physician assistants who specialize in geriatrics, and other related healthcare professionals.

REGISTRATION

To register for this CME program, please visit <http://ags2007.cerebrio.com>

Please refer to meeting ID code: **5898**.

You must be a registered AGS attendee in order to participate in this symposium.